Unknown

Dataset Information

Label-retaining liver cancer cells are relatively resistant to sorafenib.


ABSTRACT:

Objective

The standard therapy for advanced hepatocellular carcinoma (HCC) is sorafenib, with most patients experiencing disease progression within 6 months. Label-retaining cancer cells (LRCC) represent a novel subpopulation of cancer stem cells (CSC). The objective was to test whether LRCC are resistant to sorafenib.

Methods

We tested human HCC derived LRCC and non-LRCC before and after treatment with sorafenib.

Results

LRCC derived from human HCC are relatively resistant to sorafenib. The proportion of LRCC in HCC cell lines is increased after sorafenib while the general population of cancer cells undergoes growth suppression. We show that LRCC demonstrate improved viability and toxicity profiles, and reduced apoptosis, over non-LRCC. We show that after treatment w

SUBMITTER: Xin HW 

PROVIDER: S-EPMC6993136 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature